Immunomedics, Inc. (IMMU) Reports Updated Results With 90Y-Clivatuzumab Tetraxetan In Patients With Metastatic Pancreatic Cancer
5/19/2014 9:19:53 AM
NEW ORLEANS, May 19, 2014 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced that patients receiving multiple cycles of the investigational pancreatic cancer therapeutic, clivatuzumab tetraxetan labeled with yttrium-90 (90Y), in combination with low-dose gemcitabine, had increased survival advantage.
Help employers find you! Check out all the jobs and post your resume.
comments powered by